---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-002764"
form_type: "8-K/A"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2023-01-27T23:59:59+00:00"
generated_at: "2026-06-20T07:24:13.611147+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ZyVersa amends pro forma to reflect reverse merger; adds ~$105M IPR&D asset

## Summary
- Pro forma updated to forward merger (ZyVersa as VIE); ~$105M IPR&D/goodwill recorded on balance sheet.
- Combined pro forma net loss: $20.96M for 9mo Sep 2022, $8.91M for FY2021.
- Actual redemptions of 7.67M shares for $78.0M; 6.72M shares issued to ZyVersa equity holders.
- Transaction costs $5.2M settled via $1.7M Series B preferred and $3.5M cash; deferred underwriting $3.4M settled in Series B.
- Pro forma total assets $113.4M as of Sep 30, 2022, primarily from IPR&D.

## SEC filing metadata
- accession: 0001493152-23-002764
- form_type: 8-K/A
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2023-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315223002764/0001493152-23-002764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315223002764/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-002764
- JSON: https://secwatch.observer/filing/0001493152-23-002764.json
- Plain text: https://secwatch.observer/filing/0001493152-23-002764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.